Sichuan Kelun-Biotech’s New Breast Cancer Treatment Application Accepted by NMPA

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) has provided an update.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced that the National Medical Products Administration of China has accepted a new indication application for its core product, sacituzumab tirumotecan (sac-TMT), for treating advanced hormone receptor-positive, HER2-negative breast cancer. This acceptance, based on positive Phase 3 study results, marks the fourth indication for sac-TMT to undergo priority review, highlighting its potential impact on the company’s market positioning and offering new treatment options for patients.

The most recent analyst rating on (HK:6990) stock is a Buy with a HK$219.74 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.

More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company based in China, specializing in the development of antibody-drug conjugates (ADCs) targeting advanced solid tumors such as non-small cell lung cancer, breast cancer, and gastric cancer. The company holds proprietary intellectual property rights for its core product, sacituzumab tirumotecan (sac-TMT), and has licensed its development and commercialization rights outside Greater China to MSD.

Average Trading Volume: 701,173

Technical Sentiment Signal: Buy

Current Market Cap: HK$75.23B

For detailed information about 6990 stock, go to TipRanks’ Stock Analysis page.